about
Increased bioavailability of 11-keto-β-boswellic acid following single oral dose frankincense extract administration after a standardized meal in healthy male volunteers: modeling and simulation considerations for evaluating drug exposures.Comparative impact on prostanoid biosynthesis of celecoxib and the novel nonsteroidal anti-inflammatory drug CG100649.Bioactive products formed in humans from fish oils.Drug interactions with patient-controlled analgesia.Molecular clocks and the human condition: approaching their characterization in human physiology and diseasePharmacokinetics of morphine are not altered in subjects with Gilbert's syndromeGenetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.Is morphine-3-glucuronide of therapeutic relevance?Rapid genotyping for relevant CYP1A2 alleles by pyrosequencing.GCG100649, A Novel Cyclooxygenase-2 Inhibitor, Exhibits a Drug Disposition Profile in Healthy Volunteers Compatible With High Affinity to Carbonic Anhydrase-I/II: Preliminary Dose-Exposure Relationships to Define Clinical Development Strategies.A rapid screening method for a single nucleotide polymorphism (SNP) in the human MOR gene.Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.Reconstruction of peritoneal-like structure in three-dimensional collagen gel matrix culture.Identification of human cathepsin G as a functional target of boswellic acids from the anti-inflammatory remedy frankincense.Effects of the opioid remifentanil on olfactory function in healthy volunteers.The transfer half-life of morphine-6-glucuronide from plasma to effect site assessed by pupil size measurement in healthy volunteers.The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine.The influence of inhibition of probenecid sensitive transporters on the central nervous system (CNS) uptake and the antinociceptive activity of morphine-6-glucuronide in rats.Pharmacokinetic modeling to predict morphine and morphine-6-glucuronide plasma concentrations in healthy young volunteers.Does the A118G polymorphism at the mu-opioid receptor gene protect against morphine-6-glucuronide toxicity?Analgesic effects of morphine and morphine-6-glucuronide in a transcutaneous electrical pain model in healthy volunteers.Comprehensive mu-opioid-receptor genotyping by pyrosequencing.Respiratory and miotic effects of morphine in healthy volunteers when P-glycoprotein is blocked by quinidine.Effects of ABCB1 (multidrug resistance transporter) gene mutations on disposition and central nervous effects of loperamide in healthy volunteers.Single-step identification of all length polymorphisms in the UGT1A1 gene promoter.Probenecid interacts with the pharmacokinetics of morphine-6-glucuronide in humans.Non-invasive combined surrogates of remifentanil blood concentrations with relevance to analgesia.Fibroblast growth factor 21 (FGF21) is robustly induced by ethanol and has a protective role in ethanol associated liver injury.On the interference of boswellic acids with 5-lipoxygenase: mechanistic studies in vitro and pharmacological relevance.The 5-hydroxytryptamine 4 receptor agonist mosapride does not antagonize morphine-induced respiratory depression.Effects of selective COX-2 inhibition on prostanoids and platelet physiology in young healthy volunteers.Rapid identification of three functionally relevant polymorphisms in the OATP1B1 transporter gene using Pyrosequencing.A Pilot Characterization of the Human Chronobiome.Olfactory function in mild cognitive impairment and Alzheimer's disease: an investigation using psychophysical and electrophysiological techniques.Myrtucommulone from Myrtus communis: metabolism, permeability, and systemic exposure in rats.Enhanced absorption of boswellic acids by a lecithin delivery form (Phytosome(®)) of Boswellia extract.CMPF, a Metabolite Formed Upon Prescription Omega-3-Acid Ethyl Ester Supplementation, Prevents and Reverses Steatosis.Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action.The cyclooxygenase 2 genetic variant -765G>C does not modulate the effects of celecoxib on prostaglandin E2 production.Pyrosequencing™ of polymorphisms in the COX-2 gene (PTGS2) with reported clinical relevance
P50
Q34240527-971B71C9-EBB9-4FF8-8BA7-E87605260CCDQ34249714-7E1FC656-B840-4A86-9E85-E0A14C0F7AD4Q34485375-30A1F24C-532C-47D1-B008-9E4B72EFE3E8Q34515209-9ED5A3C2-AE65-4897-B351-F33CC16A5FECQ35762575-D0D37903-2086-44EF-845D-51D656F6A9B1Q35825429-DB6F7C77-5308-4197-99FA-9E1B5652B6BCQ35941387-E62D10D8-25E9-4CB4-BCDA-6B17EBAC71B2Q36176770-73C817EB-2534-4617-BD62-08F71E8B0EFEQ36321854-16FF849C-1761-4824-A9BB-EDDFC71DCD91Q39343333-DDBFF11E-B26E-4616-A08E-4B0F4396681BQ41601266-C6ACE2BB-3770-4A8D-B6E1-46B8FBF8DB2BQ42168030-D44150C2-4705-49EB-9507-0390FECE06DDQ42445908-B06D9A21-BA5D-44D6-8D99-4FD80D2F2D12Q43300254-80052564-B2E9-4D90-B0EF-9F5BDBDFF525Q43773882-3B74679D-F15B-41F9-8B42-12D7100E97E8Q43826881-11E86B73-74C5-40CB-BAC8-61AF211800BAQ43843765-F722EAEC-2B1A-4CA2-B1DE-F515E98DC372Q44092188-1E346AEA-F972-4396-A2D1-28EEDC181E06Q44110132-9D1EA784-B95C-4335-8CD1-7C008055E3ACQ44161387-B419CC11-87D6-434D-A0DB-D33D82979064Q44289543-5086CF34-9784-44D0-9D51-1CAC3DED7560Q44344617-642D29BD-3BD5-4EC3-BEB1-4DD62340EE93Q44611146-13154311-946D-42F8-88C9-20A67B9B23F7Q44635588-F8AC522D-B5CA-4F4F-A84A-82B50F6BE26CQ44817982-82EB9829-C7A0-4BF9-889C-E61E3A114DC6Q45163479-9C7DCE57-8B71-4E27-B474-F987D86D529FQ46052967-D51E7055-84A2-4FA1-8169-30AE68B5BAEFQ46120307-BD063545-5B13-4F4D-8B7D-96B40B8EBE42Q46217421-F51F1CAB-E42D-47A2-9D62-45872528326AQ46695123-94E9B51A-4339-41C8-81AC-453DAA1568C6Q46966570-73D1CFDC-7A77-401A-8F2F-4E5EA144FF90Q46974116-7988FF62-E9A3-4C8E-86D5-25249FE3B957Q47098456-9832BA3D-DF87-400B-8C9E-D949E8544DD6Q48156384-9BDCB81C-769F-4CC5-AD71-158385799669Q48296483-C168E135-4732-4952-B7D2-C75ECBC2B15EQ48324419-582FD99E-8FF8-4091-907F-01E12B07C8E3Q49379954-EA496B25-211E-4233-B24B-04126DCFC843Q51955912-5C1C5705-5787-4AD4-9FEB-AD29D8D43A00Q54566435-BE1BA63D-31C7-4A9F-9376-96D416C78BFCQ60678542-D95301F3-6000-416F-AFEF-ED139FCB30D6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carsten Skarke
@ast
Carsten Skarke
@en
Carsten Skarke
@es
Carsten Skarke
@nl
type
label
Carsten Skarke
@ast
Carsten Skarke
@en
Carsten Skarke
@es
Carsten Skarke
@nl
prefLabel
Carsten Skarke
@ast
Carsten Skarke
@en
Carsten Skarke
@es
Carsten Skarke
@nl
P106
P21
P31
P496
0000-0001-5145-3681